AdvaMed®’s National Testing Registry: Shipments of COVID-19 Molecular Diagnostic Tests Reach 100 Million

WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today announced that total U.S. shipments of COVID-19 molecular diagnostic tests reached approximately 100 million, as of July 25, based on the latest data from the association’s national testing registry. 

“The 100-million mark represents yet another extraordinary milestone as the medical technology industry ramps up to meet the demand for testing posed by the coronavirus pandemic,” said AdvaMed® president and CEO Scott Whitaker. “The diagnostics industry will continue to work 24/7, around the clock, to ensure widespread availability of test kits and supplies, doing everything possible to help beat this public health crisis.” 

Unveiled July 21, AdvaMed®’s Registry compiles information from diagnostics companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry. The registry will provide weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the U.S. to help state and federal governments in their pandemic responses. AdvaMed® and AdvaMedDx®, the association’s division of diagnostics companies, developed the National Testing Registry in partnership with 13 commercial diagnostics manufacturers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, QIAGEN, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.  

### 

 AdvaMed® member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed® members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org. 

AdvaMedDx® member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed®, AdvaMedDx® is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad. For more information, click here.